Survanta: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Adverse Reactions Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Beractant (pulmonary surfactant from natural bovine lung extr)

Indications/Uses

Prevention & treatment (rescue) of resp distress syndrome (RDS) in premature infants. Reduce incidence of RDS, mortality due to RDS & air leak complications.

Click to view Survanta detailed prescribing information

Dosage/Direction for Use

100 mg of phospholipids/kg birth wt (4 mL/kg birth wt). May administer 4 doses in the 1st 48 hr of life. Doses should be given no more frequently than every 6 hr. Prevention strategy Administer dose as soon as possible after birth, preferably w/in 15 min. Rescue strategy Give 1st dose as soon as possible after RDS is confirmed by radiographic or clinical findings, preferably by 8 hr of age.

Click to view Survanta detailed prescribing information

Overdosage

View Survanta overdosage for action to be taken in the event of an overdose.

Special Precautions

Stop dosing procedure if transient episodes of bradycardia & decreased O₂ saturation occur. Rales & moist breath sounds can occur transiently after administration. Increased probability of post-treatment nosocomial sepsis in treated infants. Frequently monitor infants w/ arterial or transcutaneous measurement of systemic O₂ & CO₂. Use in conjunction w/ experimental therapies for RDS (eg, high-frequency ventilation or extracorporeal membrane oxygenation).

Click to view Survanta detailed prescribing information

Adverse Reactions

Coagulopathy, thrombocytopenia, disseminated intravascular coagulation; adrenal hemorrhage, inappropriate antidiuretic hormone secretion; hyperphosphatemia, feeding intolerance; seizures; tachycardia, ventricular tachycardia, cardiac failure, cardio-resp arrest, increased apical pulse, persistent fetal circulation, total anomalous pulmonary venous return; hypotension, HTN, aortic thrombosis, air embolism; lung consolidation, blood from endotracheal tube, deterioration after weaning, resp decompensation & failure, subglottic stenosis, paralyzed diaphragm; abdominal distension, GI hemorrhage, intestinal perforations, volvulus, bowel infarct, stress ulcer, inguinal hernia; hepatic failure; renal failure, haematuria; fever, deterioration.

Click to view Survanta detailed prescribing information

Storage

View Survanta storage conditions for details to ensure optimal shelf-life.

Description

View Survanta description for details of the chemical structure and excipients (inactive components).

Action

View Survanta mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Other Drugs Acting on the Respiratory System

ATC Classification

R07AA - Lung surfactants ; Used in the treatment of respiratory diseases.

Thai FDA Category

Presentation/Packing

Form

Survanta intratracheal susp 25 mg/mL

Packing/Price

4 mL x 1's;8 mL x 1's

Survanta

beractant

Manufacturer:

AbbVie

Distributor:

Zuellig Pharma

Marketer:

Zuellig Pharma